Compass Therapeutics Inc. expected to post a loss of 12 cents a share - Earnings Preview

Compass Therapeutics

09/05/2025 15:17

Compass Therapeutics Inc. CMPX.OQ CMPX.O is expected to show a fall in quarterly revenue when it reports  results  for the period ending June 30 2025

​LSEG's mean analyst estimate for Compass Therapeutics Inc. is for a loss of 12 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 23.3% in the last three months. ​

Wall Street's median 12-month price target for Compass Therapeutics Inc. is $10.00​, above​ its last closing price of $1.78. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.11
-0.11
-0.12
Missed
-8.1
Dec. 31 2025
-0.10
-0.10
-0.11
Missed
-12.1
Sep. 30 2024
-0.11
-0.11
-0.08
Beat
29.4​
Jun. 30 2024
-0.09
-0.09
-0.10
Missed
-5.3
​​Mar. 31 2024
-0.11
-0.11
-0.08
Beat
29.1
Dec. 31 2023
-0.09
-0.11
Missed
-16.8​
Sep. 30 2023
-0.11
-0.11
-0.08
Beat
25.3
Jun. 30 2023
-0.08
-0.08
-0.09
Missed
-10.5

This summary was machine generated May 9 at 14:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)